ESG CEO Advisory & Management Consulting

The consultants at CRA and its subsidiary Marakon partner with executives and boards to identify industry and company specific ESG issues, and design an approach for ensuring optimal elevation and integration into company strategies and business models. We base our approach on a robust understanding of corporate “sustainability maturity,” and on how successful businesses use a range of governance, organization, resource allocation, reporting, and performance management levers to build industry leadership in the sustainability arena.

We help companies across the energy and industrial sectors better understand the growing importance of sustainability in driving stakeholder value, identify and mitigate potential ESG related risks, and create new opportunities presented by an economy-wide transition to a zero-carbon future.

CRA has the deep technical expertise to model future energy scenarios under different assumptions to assist companies in making and executing significant portfolio and resource allocation decisions that can drive long-term resilience without undue compromise on short-term performance. We support clients on market structure and rules, and help businesses navigate fast-changing regulatory frameworks.

The social and environmental impacts of ESG are felt across the pharmaceutical value chain from research and development to manufacturing, and from pricing to drug distribution to sales and marketing. CRA works with life sciences companies and global trade organizations on issues relating to pricing and access to healthcare, both of which are fundamental sustainability issues for the pharmaceutical industry.